Send me real-time posts from this site at my email
Zacks

Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST

Deciphera Pharmaceuticals, Inc. DCPH announced that the European Commission has approved its tyrosine kinase inhibitor Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (“GIST”) who have received prior treatment with three or more kinase inhibitors, including NovartisNVS Gleevec (imatinib).

We note that Novartis has lost the patent protection for some of its drugs. Gleevec faces increasing generic competition in major markets.

The nod for Qinlock in Europe was based on efficacy data from the pivotal phase III INVICTUS study as well as combined safety results from INVICTUS and the phase I study of Qinlock.

Data from the INVICTUS study showed that treatment with Qinlock led to a median progression-free survival of 6.3 months versus one month in the placebo arm and significantly reduced the risk of disease progression or death by 85%. Also, treatment with Qinlock demonstrated clinically meaningful overall survival in the study.

The approval of Qinlock in the EU was expected, since in September 2021, the European Medicines Agency’s Committee for Medicinal Products for Human Use rendered a positive opinion, recommending approval for Qinlock for the treatment of fourth-line GIST.

Shares of Deciphera have plummeted 84.8% so far this year compared with the industry’s decrease of 15.8%.

Image Source: Zacks Investment Research

We remind investors that in May 2020, the FDA approved Qinlock for treating patients with advanced GIST who were already treated with three or more kinase inhibitors, including Novartis’ Gleevec. The drug is also approved in Australia, Canada, China, Hong Kong, Switzerland and Taiwan.

In the first nine months of 2021, Qinlock generated sales worth $63.7 million. The approval in Europe should boost sales in the days ahead.

Please note that Qinlock faces competition from Blueprint MedicinesBPMC Ayvakit, which is approved for the treatment of unresectable or metastatic GIST, harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations in adults.

Blueprint Medicines is also developing Ayvakit for advanced, indolent and smoldering forms of systemic mastocytosis (“SM”). In June 2021, the FDA approved Ayvakit for treating advanced SM.

Zacks Rank & Stock to Consider

Deciphera currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Editas Medicine, Inc. EDIT, which has a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Editas Medicine’s loss per share estimates have narrowed 11.9% for 2021 and 4.1% for 2022, over the past 60 days.

Earnings of Editas Medicine have surpassed estimates in two of the trailing four quarters while missed the same on the other two occasions.


Zacks' Top Picks to Cash in on Artificial Intelligence

In 2021, this world-changing technology is projected to generate $327.5 billion in revenue. Now Shark Tank star and billionaire investor Mark Cuban says AI will create "the world's first trillionaires." Zacks' urgent special report reveals 3 AI picks investors need to know about today.

See 3 Artificial Intelligence Stocks With Extreme Upside Potential>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novartis AG (NVS): Free Stock Analysis Report
 
Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report
 
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
 
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue